Franklin Street Advisors’s Trinity Biotech TRIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2016
Q3
Sell
-3,210
Closed -$182K 191
2016
Q2
$182K Sell
3,210
-1,825
-36% -$103K 0.03% 184
2016
Q1
$294K Buy
5,035
+1,085
+27% +$57.6K 0.06% 180
2015
Q4
$232K Buy
3,950
+510
+15% +$30.1K 0.05% 198
2015
Q3
$197K Buy
3,440
+260
+8% +$20.9K 0.04% 206
2015
Q2
$287K Hold
3,180
0.05% 188
2015
Q1
$306K Buy
3,180
+790
+33% +$73K 0.06% 172
2014
Q4
$209K Sell
2,390
-3,970
-62% -$342K 0.04% 186
2014
Q3
$581K Buy
6,360
+120
+2% +$13K 0.11% 151
2014
Q2
$719K Buy
6,240
+1,160
+23% +$137K 0.14% 143
2014
Q1
$615K Buy
5,080
+650
+15% +$85.2K 0.12% 157
2013
Q4
$557K Buy
+4,430
New +$532K 0.11% 158

Other funds holding TRIB

Franklin Street Advisors's TRIB Position: Q3 2016 in Review

Franklin Street Advisors sold out of Trinity Biotech (TRIB) in Q3 2016, closing a stake of 3,210 shares — an estimated $182K sold.

Franklin Street Advisors first reported a position in TRIB in Q4 2013 and held it in 11 quarters. The position peaked at $719K in Q2 2014. 79 funds tracked by Wall St. Rank hold TRIB as of Q3 2016.

  • Franklin Street Advisors reported no remaining Trinity Biotech position as of Q3 2016 after selling out during the quarter.
  • Franklin Street Advisors sold 3,210 Trinity Biotech shares in Q3 2016, an estimated $182K.
  • Franklin Street Advisors first reported a position in Trinity Biotech in Q4 2013 and held it in 11 quarters.
  • Franklin Street Advisors's Trinity Biotech position peaked at $719K in Q2 2014.
  • 79 funds tracked by Wall St. Rank held Trinity Biotech as of Q3 2016.

Based on Franklin Street Advisors's 13F filing for Q3 2016, filed 5 Oct 2016.